Colchicine is a microtubule disassembling agent that has been known for a long time. As this historic agent inhibits polymerization of α, β-tubulin heterodimers of microtubules^[@r1]^, colchicine has many microtubule-related medicinal virtues. For example, colchicine has been appreciated as a medical drug for treating gout^[@r2],[@r3]^, pericarditis^[@r4],[@r5]^, and dermatological disorders^[@r6]^ and as an immune suppressant^[@r7]^. Moreover, drugs related to colchicine are anticipated to be chemotherapeutic agents, because they inhibit cell division and vascularization of tumors^[@r8]^.

At the same time, the cardiotoxicity of colchicine and other microtubule disassembling agents has been recognized in situations of unexpected use for medical treatment^[@r9]^, acute poisoning by ingesting plants containing microtubule disassembling agents^[@r10],[@r11]^ and side-effects of chemotherapeutic use^[@r12],[@r13],[@r14]^. Moreover, it has been suggested that colchicine may have a toxic effect on cardiac impulse generation and conduction in humans^[@r10]^. Experimental studies have demonstrated that colchicine induces impairment of the intrinsic contractility of the myocardium^[@r15]^ and histopathologic changes in the heart^[@r16],[@r17]^.

As cardiotoxicity could directly lead to mortality, colchicine and related drugs require especially careful empirical study in nonclinical studies for pharmaceutical development. In such a case, analysis of the rat electrocardiogram (ECG) might provide valuable data about the quality and magnitude of cardiotoxicity. Indeed, the utility of rat ECG analysis in toxicology has been claimed in the last few years^[@r18]^. Nevertheless, few *in vivo* experimental studies have been reported, and less is known about the electrocardiographic changes induced by colchicine in experimental animals. Therefore, we examined the acute cardiotoxicity of colchicine in rats by ECG analysis, in addition to blood chemical and histopathological analyses.

Electrocardiographic experiments were performed using 3 male Crl:CD(SD) rats (Charles River Laboratories Japan, Kanagawa, Japan). At 5 weeks of age, a small telemetry device (weight = 3.9 g, volume = 1.9 cc; TA10ETA-F20, Data Sciences International, New Brighton, MN, USA) for transmitting ECG data was implanted into the dorsal subcutaneous region under systemic anesthesia with pentobarbital sodium. Paired wire electrodes that came with the telemetry device were placed under the skin of the dorsal and ventral thorax to record the apex-base (A-B) lead ECG. One week after the surgery, ECG signals were recorded from each rat in a cage that had been placed on a signalreceiving board (RA1610, Data Sciences International, New Brighton, MN, USA). ECG data were continuously sampled at 1 msec intervals, and all data analysis of ECG-wave components was performed using an ECG processor analyzing system (SRV2W, Softron, Tokyo, Japan) equipped on a personal computer in series with an analog-digital converter; the ECG data were stored on an external hard disk. During the period of ECG recording, 1.25 mg/kg colchicine (Wako Pure Chemical Industries, Osaka, Japan) dissolved in 5% glucose at a volume of 1 mL/kg was administered intravenously into the rats once daily for 2 consecutive days. This dosing schedule for colchicine is known to induce histopathological changes in the rat heart based on our previous study^[@r17]^. The ECG-wave components (RR interval, QRS duration, PR interval and QT interval) were analyzed in 10 consecutive beats, and power spectral analysis of heart rate variability was performed at 23, 21, 18 and 12 hours before the first injection; 1, 3, 6, 12 and 23 hours after the first injection; and 1, 3, 6 and 12 hours after the second injection. The frequency component of the RR interval on ECG was analyzed based on the Cooley-Tukey Fast Fourier Transform algorithm^[@r19]^. Two major spectral components, low frequency (LF: 0.1 -- 1.0 Hz) and high frequency (HF: 1.0 -- 3.0 Hz) power, were detected, and then the HF power was used as an index of parasympathetic nervous activity; the LF/HF ratio was used as an index of balance between sympathetic and parasympathetic nervous activity^[@r20]^.

Histopathological and blood chemical experiments were performed using 6 male Crl:CD(SD) rats (Charles River Laboratories Japan, Kanagawa, Japan). At 6 weeks of age, colchicine (Sigma-Aldrich, Tokyo, Japan) or vehicle (5% glucose) was administered (n = 3/group) once daily for 2 consecutive days. On the day after the last administration, 18-hour fasted animals were given pentobarbital anesthesia, and blood samples were collected from the abdominal aorta. Blood samples were treated with heparin to obtain plasma, and aspartate aminotransferase (AST), lactate dehydrogenase (LDH1--5), creatine kinase (CK-MM, MB, BB and m-CK), calcium (Ca), inorganic phosphorus (InP), Na^+^, K^+^ and Cl^-^ were analyzed. Moreover, cardiac troponin T (cTnT) in heparinized whole blood was measured, and a semiquantitative result was obtained according to an earlier report^[@r21]^ with a Trop T sensitive kit (Roche Diagnostics, Tokyo, Japan), a monoclonal antibody-based immunoassay kit. After collection of whole blood, the heart, gastrocnemius muscle, liver, kidneys and stomach were extracted and immediately fixed in 10% neutral phosphate-buffered formalin. Also, hearts were cross-sectioned at one point in atria with the atrioventricular node and two points in ventricles as described in our previous report^[@r17]^. Fixed organs were embedded in paraffin and sectioned at a thickness of 4--6 μm. The specimens were stained with hematoxylin and eosin (HE) or subjected to immunohistochemical staining with anti-cleaved caspase-3 rabbit polyclonal antibody (Cell Signaling Technology, Danvers, MA, USA) followed by horseradish peroxidase-labeled goat antibody against rabbit Ig (Dako, Tokyo, Japan), and visualized with 3,3'-diaminobenzidine. Observation of these specimens was performed using a light microscope (BX51, Olympus Corporation, Tokyo, Japan). In addition, blood chemical experiments for the rats administered 1.25 mg/kg colchicine a single time intravenously (n = 3) were performed separately 24 hours after injection in a similar way.

Electrocardiographic analysis revealed that the RR interval and QT interval were prolonged at 1 hour after the second injection of colchicine ([Fig. 1A, D, E](#fig_001){ref-type="fig"}Fig. 1.Time-response curves of the RR interval (A), QRS duration (B), PR interval (C), QT interval (D) and QT-RR plot (E) before and after injections of colchicine. Arrows indicate time points of colchicine injection. White bars and filled bars on horizontal axes indicate the light period and dark period, respectively. Error bars indicate the SE.). The QRS duration and PR interval became gradually prolonged beginning at the first injection of colchicine ([Fig. 1B, C](#fig_001){ref-type="fig"}). The results of power spectral analysis showed that the LF/HF ratio, as an index of balance between sympathetic and parasympathetic nervous activity, decreased at 6 hours after the second injection ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Time-response curves of the LF/HF ratio (A) and HF power (B) before and after injections of colchicine. The LF/HF ratio is an index of balance between sympathetic and parasympathetic nervous activity, and HF power is an index of parasympathetic nervous activity. Arrows indicate time points of colchicine injection. White bars and filled bars on horizontal axes indicate the light period and dark period, respectively. Error bars indicate the SE.). The HF power, as an index of parasympathetic nervous activity, increased at 1 hour after the second injection of colchicine ([Fig. 2B](#fig_002){ref-type="fig"}).

Regarding the blood chemical data, high levels of AST, LDH (1--5), CK (CK-BB, CK-MB, CK-MM and m-CK) and cTnT and a low level of Ca were detected in rats treated with colchicne once ([Table 1](#tbl_001){ref-type="table"}Table 1.Blood Chemical Data of Rats Administered Colchicine or 5% Glucose). Moreover, low and varying levels of InP, K^+^ and Cl^−^ in plasma were detected ([Table 1](#tbl_001){ref-type="table"}). These changes were more clear in rats treated with colchicine twice ([Table 1](#tbl_001){ref-type="table"}).

Histopathologically, colchicine-treated rats showed degeneration, with eosinophilic granules and vacuolation in the sarcoplasm of myocardial cells ([Fig. 3B](#fig_003){ref-type="fig"}Fig. 3.Micrograph of lesions in the hearts of rats treated with colchicine or 5% glucose twice A: Normal left ventricular wall of a rat given 5% glucose. B: Degeneration with eosinophilic granules and vacuolation in sarcoplasm (arrowheads) of myocardial cells and pyknosis, karyorrhexis and mitotic figures (white arrows) of interstitial cells in left ventricular wall of a rat given colchicine. A high magnification view of the eosinophilic granules and vacuolation in sarcoplasm enclosed by a black rectangle is shown in the upper right. C: Almost no cleaved caspase-3-positive cells in the normal myocardium of a rat given 5% glucose. D: Cleaved caspase-3-positive cells (arrows) in the intersititial cells of the myocardium, which showed pyknosis, karyorrhexis and mitotic figures. E: Normal atrioventricular node of a rat given 5% glucose. F: Atrioventricular node of a rat given colchicine with no remarkable findings. E: Normal endocardial cells of a rat given 5% glucose. H: Pyknosis, karyorrhexis and mitotic figures (arrow) of endocardial cells of a rat given colchicine. A, B and D--H: H-E staining, bars = 40 µm. C and D: Immunohistochemical staining for cleaved caspase-3, bars = 40 µm.). These lesions were diffused and extended throughout the ventricles but were most prominent around the interventricular septum and left ventricular wall of the cardiac apex. Moreover, pyknosis, karyorrhexis and mitotic figures of interstitial cells and endocardial cells, which were positive for cleaved caspase-3, were observed ([Fig. 3B, D and H](#fig_003){ref-type="fig"}). The atrioventricular nodes of colchicine-treated rats showed no remarkable findings ([Fig. 3F](#fig_003){ref-type="fig"}).

Skeletal muscle of colchicine-treated rats showed vacuolation in the sarcoplasm ([Fig 4A](#fig_004){ref-type="fig"}Fig. 4.Micrograph of lesions in the gastrocnemius muscle, liver, kidney and stomach of rats treated with colchicine twice. A: Vacuolation in sarcoplasm (arrows) of the gastrocnemius muscle of a rat treated with colchicine. B: Single-cell necrosis (arrowheads) and increase in mitotic figures (arrows) of midlobular hepatocytes of a rat treated with colchicine. C: Pyknosis (arrowheads) and increase in mitotic figures (arrows) of the tubular epithelium in the kidney of a rat treated with colchicine. D: Pyknosis (arrowheads) of the collecting duct in the kidney of a rat treated with colchicine. E: Pyknosis (arrowheads) and increase in mitotic figures of the mucosal epithelium of the stomach of a rat treated with colchicine. A--E: H-E staining, bars = 40 µm. C and D: Immunohistochemical staining for cleaved caspase-3, bars = 40 µm.). The livers of colchicine-treated rats showed single-cell necrosis and an increase in mitotic figures in midlobular hepatocytes ([Fig. 4B](#fig_004){ref-type="fig"}). The kidneys of colchicine-treated rats showed pyknosis and an increase in mitotic figures in the tubular epithelium and collecting ducts ([Fig. 4C, D](#fig_004){ref-type="fig"}). The stomach of a rat treated with colchicine showed pyknosis and an increase in mitotic figures in the mucosal epithelium ([Fig. 4E](#fig_004){ref-type="fig"}).

In this study, colchicine exhibited cardiotoxicity, in addition to myotoxicity, hepatotoxicity, nephrotoxicity and gastrointestinal toxicity, which was consistent with reports in humans^[@r22]^. Not only high levels of cardiac injury-related blood chemical parameters, i.e., AST, LDH 1, LDH 2, CK-MB and cTnT, and histopathological changes in the heart, i.e., degeneration with eosinophilic granules and vacuolation in the sarcoplasm of myocardial cells, but also electrocardiographic changes, i.e., prolongation of the RR interval, QRS duration, PR interval and QT interval, were detected. Prolongation of the RR interval suggested a decrease in heart excitability induced by disturbance of impulse initiation. This change is usually produced by alteration of the sinoatrial rhythm^[@r23]^. Prolongation of the QRS duration and PR interval suggested abnormality of the atrioventricular and ventricular conduction system. These decreases in excitability and conductivity of the heart were considered to be related to colchicine-induced bradycardia and atrioventricular block in humans.

Moreover, it is suggested that the increase in parasympathetic nervous activity affected prolongation of the RR interval and QT interval because these changes occurred at the same time as the increase in HF power. Prolongation of the RR interval induced by parasympathetic nervous activity may affect prolongation of the QT interval. The reason for the hyperactivity of the parasympathetic nerve after the second injection remains to be elucidated. The LF/HF ratio was not decreased at 1--3 hours after the second injection in spite of an increase in HF power after 1 hour. So, it is likely that sympathetic nervous activity also increased slightly at 1--3 hours after the second injection but calmed down until 6 hours after. The effect of the sympathetic nerve on the ECG data was thought to be little because any changes in the ECG waveform corresponded to this sympathetic nervous change. As for prolongation of the QT interval, a factor other than prolongation of the RR interval affected this change because the QT interval after the second injection was prolonged compared with that after the first injection even though the RR intervals in both cases were similar in length. The low level of Ca in blood induced by colchicine might affect this change, especially after the second injection, in addition to prolongation of the RR interval. It has been reported that a 20% decrease in the blood Ca level induced prolongation of the QT interval^[@r24]^. In this study, the blood Ca level of the rats treated with colchicine twice decreased by about 20%. However, this effect of a low Ca level is not severe because the QT interval at 24 hours after the first injection did not prolong remarkably when the blood Ca level decreased by about 10%. The cause of the low blood Ca level was considered to be related to impaired bone cell calcium homeostasis in colchicine-treated rats^[@r25]^.

The decrease in conductivity was suggested to be induced by not only the increase in parasympathetic nervous activity, because prolongation of the QRS duration and PR interval occurred earlier than the increase in HF power. Degeneration of ventricular myocardial cells was slight, and no change in the atrioventricular node was observed. So it might be difficult to consider histopathological change in the heart as the main preceding cause of the decrease in conductivity.

In contrast to the results of our present study, several *in vitro* studies have revealed that colchicine stimulates beating cardiac myocytes^[@r26]^ and enhances calcium and sodium currents in cardiac myocytes^[@r27],[@r28]^ at 1--15 μM. The C~max~ of rats administered 1.5 mg/kg colchicine intravenously was estimated to be approximately 3 μM^[@r29]^. So, it is likely that the exposure level in the current experiment (1.25 mg/kg intravenously) reached the concentration at which colchicine affects beating, Ca and Na currents of cardiac myocytes, at least, instantaneously, suggesting that colchicine might induce an increase in excitability and conductivity in the present experiment. The reason for this difference between the previous results *in vitro* and the current results *in vivo* was not clarified in this study. Also, prolongation of the QRS duration and PR interval persisted over 12 hours after the injections even though the half-life in blood of colchicine is short. This might be associated with secondary causes such as the low level of Ca and variation of electrolytes in plasma, which are thought to be related to injuries of the bone, kidney and gastrointestinal tract. It has been reported that in the case of colchicine poisoning by oral ingestion in humans, serious cardiac events occurred at 24--36 hours after ingestion. So, cardiac events of colchicine poisoning are thought to be induced by not only direct effects on cardiac myocytes but also secondary causes such as changes in autonomic nervous activity and/or changes in body fluid composition. The results of this study concerning the autonomic nerve and biochemistry may suggest this secondary cause. In addition, the cardiotoxicity of the metabolites of colchicine must be discussed. However, the toxicity of the metabolites of colchicine is unknown. In order to further elucidate the relation between decreases in excitability and conductivity, the changes in electrolytes and metabolites of colchicine, time-response changes and dose-response changes of electrolytes in blood, colchicine metabolism and ECG parameters must be assessed in detail.

In conclusion, electrocardiographic changes indicating decreased excitability and conductivity of the myocardium, in addition to blood chemical and histopathological changes, were detected in rats intravenously administered colchicine. It is thought that decreased excitability and conductivity of the myocardium were related to an increase in parasympathetic nervous activity and a low level of blood Ca.
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